Ipca LaboratoriesQ2 FY25

Ipca Laboratories Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,834.4P/E: 32.3Market Cap: ₹46.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
- U.S. business revenue around INR400 crores historically, with both formulations and API contributing; growth expected due to new product launches with Unichem collaboration. - Generic business (excluding Unichem) expected to grow around 8% in FY '25. - Overall generic business growth forecasted between 10-12% for the current financial year. - Plans to launch 6-7 molecules in the U.S. market in the current financial year, with about 13-15 products over two years. - Subsidiaries like Trophic Wellness growing at 10-12% top line and 15-20% bottom line; Onyx Scientific steady despite market challenges. - Pisgah currently underperforming but expected to improve due to project ramp-up. - Good growth expected from expansion in markets beyond the U.S., including ROW, Europe, Australia, New Zealand, and Canada through Unichem. - Domestic business productivity improving with around 7,000 medical reps and steady sales force expansion. Overall, steady growth with new molecule launches and geographical expansion are key drivers.

See what Ipca Laboratories management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript on page 18 and surrounding pages does not mention any current or future plans for fundraising through debt or equity. Key points related to financial and operational updates are: - No specific reference or disclosure regarding new debt or equity fundraising. - Discussion mainly focused on business operations, revenue guidance, subsidiaries' performance, and market conditions. - Emphasis on consolidation effects with Unichem and expected performance in generics and global markets. - No indications of planned capital raising initiatives during the call. Thus, there is no information provided in the available transcript about any current or future fundraising activities via debt or equity.

See what Ipca Laboratories management said on order book — free account, 30 seconds.

Capex plans

Yes
  • No direct mention of specific current or future capex or strategic investment plans is found on page 18 or surrounding pages.
  • The discussion mainly focuses on business performance, revenue guidance, subsidiaries' progress, product launches, and market growth.
  • Subsidiaries like Trophic Wellness and Onyx Scientific are growing steadily, with Pisgah anticipated to improve.
  • Launch of 6-7 molecules in the U.S. in the current financial year is on track, which implies ongoing investment in product development.
  • There is mention of continued R&D investment around 3% to 4% of turnover, expected to increase to about 4.25% to 4.5% next financial year due to biotech work and clinical batches.
  • No explicit capital expenditure figures or major strategic capital investments discussed in this transcript excerpt.

Track Ipca Laboratories — get its next earnings analysis in your feed

How does Ipca Laboratories rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisIpca Laboratories
Rev 3Mar 3

How does Ipca Laboratories rank in Pharmaceuticals & Biotechnology?

Compare Ipca Laboratories against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →